Association between the early high level of serum tacrolimus and recurrence of hepatocellular carcinoma in ABO-incompatible liver transplantation

Figure 2 Long-term graft outcomes of the non-hepatocellular carcinoma subgroup (n = 41) and their associations with tacrolimus trough concentration. A: Comparison of tacrolimus concentrations in the graft failure (n = 10) and graft survival (n = 31) groups at each time point; B: A graph comparing tacrolimus concentrations at 24 wk post- liver transplantation (LT) in the graft loss (n = 10) and graft survival (n = 31) groups; C: Survival curves according to tacrolimus trough concentration at 24 wk post-LT (> 5.4 ng/mL, n = 21 vs ≤ 5.4 ng/mL, n = 14). Patients for whom tacrolimus concentration was not reported at 24 weeks were excluded from the analyses. ABOi: ABO-incompatible; FK: Tacrolimus; HCC: Hepatocellular carcinoma; LT: Liver transplantation.